SELLAS Life Sciences Group, Inc
SLS
Positions held
Your positionsSLS isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- SELLAS Life Sciences operates in the biotechnology sector, which has significant growth potential as new therapies and treatments are developed.
- The company's market cap is approximately $2.29 billion, indicating a substantial valuation in the healthcare market.
- SELLAS has a target mean price of $32.5, suggesting potential upside from its current trading levels.
- SELLAS Life Sciences has reported zero revenue for multiple quarters, indicating a lack of commercial success.
- The company has a negative profit margin of 0.0% and has consistently posted net losses, including -$37.34 million in 2023.
- SELLAS has a score of -11.00, with a 'Sell' signal based on various technical indicators, reflecting bearish market sentiment.
Fundamentals
| Market cap | $2.27B | Enterprise value | $2.14B | Trailing P/E | — | Forward P/E | -112.60 |
| PEG | — | Price / book | 16.51 | Beta | 2.57 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -39.6% | ROA | -23.3% | Debt / equity | 0.01 |
| Current ratio | 18.83 | Free cash flow | -$16.38M | Analyst recommendation | none | Mean target | $32.50 |
| 52w high | $15.88 | 52w low | $1.39 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$9.6M | -$8.4M | -$7.7M | -$6.8M | -$6.6M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$10.6M | -$9.3M | -$8.3M | -$7.1M | -$6.9M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $1.0M | — |
| Op margin | — | — | — | -3195.0% | — |
| Net income | -$26.9M | -$30.9M | -$37.3M | -$41.3M | — |
| Gross margin | — | — | — | 90.0% | — |
| Gross profit | — | — | $0.0M | $0.9M | $7.4M |
| Operating income | -$28.3M | -$31.5M | -$37.9M | -$31.9M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · SLS Stock’s 2-Week Rally Loses Steam: Retail Sees ‘Peanut Prices’ As Fresh AML Study Fuels Regal Hopes
2026-10-02 · SLS, IBRX Stocks Climb Overnight: Retail Eyes Moderna’s Rally As MRNA Lands A Nasdaq-100 Spot
2026-10-01 · SLS Stock Snaps 3-Quarter Winning Streak — Retail Traders Speculate On Buyout, Eye Lease Through 2027
2026-10-01 · Despite Heavy Hedge Fund Support, Why Sellas Life Sciences (SLS) Fell 16.6% in Q3
2026-10-01 · Can SELLAS Life Sciences (SLS) Turn Early CDK9 Pancreatic Data Into a Durable Oncology Edge?
2026-09-30 · SELLAS Life Sciences Group (SLS) Stock May Be Trading At A Premium On Fresh Pancreatic Cancer Data
2026-09-30 · SELLAS Life Sciences Group (SLS) Could Be Fully Priced After Fresh SLS009 Pancreatic Data
2026-09-30 · Biotech Lagged The Broader Market In September — Did Retail Favorites SLS, IBRX, VNDA And IOVA Dodge XBI’s Slump?
2026-09-25 · SLS Stock Slips 3% As Pancreatic Cancer Lab Data Leave REGAL Wait Unanswered
2026-09-24 · SLS Stock Slips Overnight Ahead Of Pancreatic Cancer Conference — Retail Looks For Clues To SLS009’s Next Trial
Price (daily)
Full chart · RSI · MACD · patterns